2021 World Conference on Lung Cancer (Posters)-FP09. Impact of Brain Metastasis Status on Adverse Events (AEs) Requiring Dose Reduction Among Patients Receiving Lorlatinib

FP09. Impact of Brain Metastasis Status on Adverse Events (AEs) Requiring Dose Reduction Among Patients Receiving Lorlatinib

Back to course

Video Transcription

Video Summary

The study conducted a retrospective review of 130 patients who received lorlatinib for ALK-positive and ROS1-positive non-small cell lung cancers. The impact of brain metastasis on adverse events requiring dose reduction was explored. Out of the total study population, 82% had pretreatment brain metastasis. Cognitive effects, mood effects, and speech effects were the most common adverse events requiring dose reduction in patients with brain metastasis. However, there were no statistically significant differences when comparing the frequency of adverse events between patients with and without brain metastasis. Dose reductions occurred early for both groups. Further research is needed to understand the mechanisms of CNS adverse events in lorlatinib treatment.

Asset Subtitle

John F Murphy

Meta Tag

Speaker John F Murphy

Topic Novel Therapeutics and Targeted Therapies

Keywords

retrospective review

lorlatinib

ALK-positive

ROS1-positive

non-small cell lung cancers